Recent large funding rounds and secondary market transactions have propelled Neuralink’s private valuation estimates into the $28–42 billion range as of early October 2026, up sharply from the $9–10 billion post-money level of its 2025 Series E. Multiple 2026 financings totaling several billion dollars, alongside clinical milestones such as expanded human implants for paralysis and speech restoration plus preclinical Blindsight progress, underpin trader focus on whether the company crosses the queried threshold by month-end. Secondary share prices around $150 reflect sustained investor appetite for brain-computer interface assets amid broader sector funding, including a recent $1 billion round for competitor Precision Neuroscience. With resolution just weeks away, near-term data releases or additional capital raises represent the key swing factors.